Top 20 Pharmaceutical Company in Bangladesh 2024

This article provides a detailed overview of the Top 20 Pharmaceutical Company in Bangladesh 2024.

The pharmaceutical industry in Bangladesh has experienced significant growth over the past decades. As of 2024, the market size is approximately $3.32 billion, with projections to reach $6.68 billion by 2027.

This growth is driven by factors such as rising life expectancy, increasing per capita income, changing disease profiles, and a growing population.

In terms of global market share, Bangladesh’s pharmaceutical exports have expanded to 157 countries, with export earnings totaling $175.425 million in FY 2022-23. This reflects a slight decrease from the previous fiscal year’s $188.78 million FY 2021-22.

While the country’s share in the global pharmaceutical market remains modest, the consistent growth in exports indicates a strengthening presence internationally.

The industry is dominated by local companies, which account for more than 90% of the market share. Notable firms include Square Pharma, Incepta Pharma, and Beximco Pharma.

The government has also implemented favorable policies, such as the establishment of the Active Pharmaceutical Ingredients (API) Industrial Park, to reduce dependence on imports and enhance self-sufficiency.

However, challenges persist, including a heavy reliance on imported raw materials and the impending loss of patent exemptions due to the country’s graduation from the least-developed country status. Addressing these issues will be crucial for sustaining and enhancing the industry’s growth trajectory.

Here is an overview of the top 20 pharmaceutical company in Bangladesh, including key information about each:

1. Square Pharmaceuticals Ltd.

Square Pharmaceuticals Ltd., founded in 1958 by Samson H. Chowdhury and three associates. The company has grown into a prominent player in the global pharmaceutical arena. This is the flagship company of Square Group and has maintained a leading position in Bangladesh’s pharmaceutical industry since 1985. Through its commitment to quality, innovation, and ethical business practices, Square Pharmaceuticals continues to play a pivotal role in enhancing healthcare both in Bangladesh and internationally.

Head office: SQUARE Centre, 48, Mohakhali Commercial Area, Dhaka 1212, Bangladesh.

Factory: Square Cephalosporins Ltd. Kaliakoir, Gazipur.

Square Formulations Ltd.  Momin Nagar, Gorai, Mirzapur, Tangail

Square Lifesciences Limited.  Pabna Patikabari, Hemayatpur, Pabna

Square Pharmaceuticals PLC, (Chemical Division). Pabna Salgaria, Pabna

Square Pharmaceuticals PLC, Gazipur.  Kaliakair, Gazipur

Square Pharmaceuticals PLC. Salgaria, Pabna, Bangladesh.

Total Products: 669 pharmaceutical products, along with agro-vet products, pesticides, pellets, and basic chemicals

Export Facilities: The Company has a significant presence in the international market, exporting products to over 45 countries across Asia, Africa, Europe, Central and South America, and Oceania.

Total Revenue: Approximately BDT 5,264 Crore

Growth Rate: -3.57% Year Over Year

Market Share: 17.73% in the Bangladeshi pharmaceutical market

Flagship Products: Some of the company’s flagship products include Seclo (Omeprazole), Neuro-B (Vitamin B1, B6 & B12), Calbo-D (Elemental Calcium + Vitamin D3), Cef-3 (Cefixime Trihydrate), and Zimax (Azithromycin Dihydrate).

Accreditations: Square Pharma has received accreditations from several international regulatory bodies, including the UK MHRA and the US FDA, affirming its adherence to global quality standards. Complies with international standards; first Bangladeshi company to set up a manufacturing plant in Nairobi, Kenya

Related: Top 10 Pharmaceutical Companies in USA 2024

2. Incepta Pharmaceuticals Ltd.

Incepta Pharmaceuticals Ltd., established in 1999, has rapidly emerged as one of Bangladesh’s leading pharmaceutical companies. With state-of-the-art manufacturing facilities located in Savar and Dhamrai, near Dhaka, Incepta produces a diverse range of dosage forms, including tablets, capsules, oral liquids, ampoules, dry powder vials, nasal sprays, eye drops, creams, ointments, and human vaccines. The company’s commitment to innovation is evident in its introduction of over 295 products that were “first ever in Bangladesh,” contributing to a portfolio of more than 1,100 products as of 2023.

Head Office: 40 Shahid Tajuddin Ahmed Sarani, Tejgaon Industrial Area, Dhaka-1208.

Factory: Incepta operates two major manufacturing facilities: one in Savar, and another in Dhamrai, about 53 kilometers away.

Total Products: Incepta has developed over 1,100 products, with 14 new introductions that year alone, including capsules, tablets, nasal sprays, and eye drops

Export Facilities: The company exports its products to 98 countries worldwide

Total Revenue: Approximately BDT 3,730 Crore

Growth Rate: +6.52% Year Over Year

Market Share: 10.21% in the Bangladeshi pharmaceutical market

Flagship products: Pantonix (Pantoprazole Sodium), Montair (Montelukast Sodium), Osartil (Losartan Potassium), Omidon (Domperidone Maleate), and Fixocard (Amlodipine Besilate + Atenolol). Accreditations: WHO Prequalification GMP Certificate, UK MHRA GMP Certificate, Health Canada GMP Certificate, Germany GMP Certificate, Turkey GMP Certificate, Taiwan GMP Certificate, Philippines GMP Certificate, Moldova GMP Certificate, Yemen GMP Certificate, Kenya GMP Certificate, Uganda GMP Certificate, Democratic Republic of Congo GMP Certificate, Ethiopia GMP Certificate.

3. Beximco Pharmaceuticals Ltd.

Beximco Pharmaceuticals Limited is one of Bangladesh’s top producers and exporters. When the company was first established in 1976, it sold its goods locally after importing goods from Upjohn, USA, and Bayer, Germany. Beximco Pharma started producing these goods in 1980 via a license agreement, and in 1983 it introduced its own formulation brands. Beximco Pharma has expanded steadily since its modest beginning. It is now one of the region’s leading generic pharmaceutical companies.

Head Office:  19 Dhanmondi R/A, Road No. 7, Dhaka 1205, Bangladesh.

Factory: Plant-1: Tongi I/A, Gazipur.  Plant-2: Kaliakoir, Gazipur

Total Products: As of the latest available data, Beximco Pharma produces more than 400 generics in various dosage forms covering diverse therapeutic categories.

Export Facilities: Beximco Pharma is the largest exporter of pharmaceuticals in Bangladesh, with a global footprint in more than 50 countries including those of the USA, Europe, Australia, Canada, Latin America, and South Africa.

Total Revenue: Approximately BDT 2,990 Crore

Growth Rate: +4.15 % Year Over Year

Market Share: Beximco Pharma holds a market share of approximately 9.53% in the Bangladeshi pharmaceutical market.

Flagship Products: Some of the company’s top brands include: Napa (Paracetamol), Napa Extra (Paracetamol + Caffeine), Bizoran (Amlodipine Besilate + Olmesartan Medoxomil), Atova (Atorvastatin Calcium), Acifix (Rabeprazole Sodium).

Accreditations: Beximco Pharma’s manufacturing facilities have been certified by major global regulatory authorities, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Australia’s Therapeutic Goods Administration (TGA), Health Canada, and others.

Related: Global Top 20 Pharmaceutical Companies in 2024

4. Healthcare Pharmaceuticals Limited

In 1988, Healthcare began its journey by forming Healthcare Distribution Limited in partnership with Roche Limited, a well-known global corporation with headquarters in Switzerland. Prior to 2001, HPL was in charge of bringing in and supplying Roche goods to the regional market.

In order to manufacture the goods that are imported from Roche, Switzerland, and other local generics for the domestic market, HPL made the decision to build its own pharmaceutical facility in 1996.

In nearly every therapeutic class, HPL produces approximately two hundred medicines in a variety of dosage forms, including tablets, capsules, liquids, dry syrups, creams and ointments, gels, small volume parenteral, and eye drops. Additionally, a large number of items are being developed for both domestic and international markets in Asia, Africa, and the CIS area.

The facility was designed and validated with support from Roche technical experts from Basel, Switzerland, adhering to Good Manufacturing Practices (GMP).

Head Office: Nasir Trade Centre (NTC), Level-9 & 14, 89 Bir Uttam CR Datta Road, Banglamotor (Sonargaon Road), Dhaka-1205, Bangladesh.

Factory: Mirzapur Bazar, Rajendrapur, Gazipur-1703, Bangladesh. Contact No.: +880 18888 19001, +88-02-9201438-41, Fax: +88-02-9201437.

Total Products: HPL produces over 210 branded products of 120 generics across various dosage forms, including tablets, capsules, liquids, dry syrups, creams, ointments, gels, small volume parenterals, and eye drops, covering almost all therapeutic classes.

Export Facilities: HPL exports its products to markets in Asia, Africa, and the Commonwealth of Independent States (CIS) region. The company has received certifications from international pharmaceutical regulatory authorities such as TGA (Australia), NPRA (Malaysia), MCAZ (Zimbabwe), and TFDA (Tanzania), facilitating its global reach.

Total Revenue: Approximately BDT 2,269 Crore

Growth Rate: +4.58% Year Over Year

Market Share: The company holds a market share of 7.36% in the Bangladeshi pharmaceutical industry.

Flagship Products: Some of HPL’s top brands include: Sergel (Esomeprazole), Alcet (Levocetirizine Dihydrochloride), Angenta (Flupentixol + Melitracen), Denvar (Cefixime Trihydrate), Emistat (Ondansetron)

Accreditations: HPL has obtained certifications from several international regulatory authorities, including: Therapeutic Goods Administration (TGA) Australia, National Pharmaceutical Regulatory Agency (NPRA), Malaysia, Medicines Control Authority of Zimbabwe (MCAZ), Tanzania Food and Drugs Authority (TFDA)

5. Renata PLC

Renata PLC, formerly known as Pfizer (Bangladesh) Limited, is a prominent pharmaceutical and animal health product company in Bangladesh. Established in 1972 as a subsidiary of Pfizer, the company transitioned to local ownership in 1993 and adopted the name Renata Limited. It is currently the fourth-largest pharmaceutical company in Bangladesh and the market leader in animal health products.

Head Office: Plot 1, Milk Vita Road, Section-7, Mirpur, Dhaka-1216, Bangladesh.

Factory: Plant Unit-1: Plot No. 1, Sec-7, Milk Vita Road, Mirpur, Dhaka, Bangladesh.

               Plant Unit-2: Rajendrapur, Gazipur, Bangladesh.

              Plant Unit-3: Kashor, Hobirbari, Bhaluka, Mymensingh, Bangladesh.

Total Products: The company manufactures approximately 300 generic pharmaceutical products, including hormones, contraceptives, anti-cancer drugs, oral preparations, cephalosporins, and parenteral preparations.

Export Facilities: Renata exports its products to various countries, including Afghanistan, Belize, Cambodia, Ethiopia, Guyana, Honduras, Hong Kong, Kenya, Malaysia, Myanmar, Nepal, the Philippines, Sri Lanka, Thailand, the United Kingdom, and Vietnam.

Total Revenue: Approximately BDT 1,559 Crore

Growth Rate: +5.57% Year Over Year

Market Share: 4.97% in the Bangladeshi pharmaceutical market

Flagship Products: Some of Renata’s notable products include Maxpro, Rolac, Fenadin, Rolip, and Furoclav.

Accreditations: Renata’s Potent Product Facility has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA), enabling the company to export prednisolone to the UK.

6. Opsonin Pharma Ltd.

Opsonin Pharma Ltd. (OPL) is one of the leading pharmaceutical companies in Bangladesh, dedicated to developing, manufacturing, and marketing generic medicines for human use. Established in 1956, OPL has a long-standing reputation for providing quality medicines at affordable prices.

Head Office: Opsonin Building, 30 New Eskaton Road, Ramna, Dhaka 1000. Contact No.: (+880-02) 48311900, 55142000. Email: info@opsonin.net.

Factory: Opsonin Pharma Limited’s manufacturing facility is located in Rupatali, Barishal, Bangladesh. Contact No.:  (+88 024788) 71843-50.

Total Products: The company manufactures more than 350 brands with over 800 SKUs of pharmaceutical finished products.

Export Facilities: OPL began exporting its products in 1985 and has since expanded its presence to around 25 countries across Asia, Africa, the Middle East, Central America, and Oceania.

Total Revenue: Approximately BDT 1,431 Crore

Growth Rate: +4.27% Year Over Year

Market Share: 3.90% in the Bangladeshi pharmaceutical market

Flagship Products: Some of OPL’s top brands include: Finix (Rabeprazole Sodium), Bislol (Bisoprolol Fumarate), Clavusef (Cefuroxime Axetil + Clavulanic Acid), Beklo (Baclofen), Pregaba (Pregabalin)

Pase (Clonazepam), Trilock (Montelukast Sodium), Zovia Gold (Multivitamin & Multimineral), Esotid (Esomeprazole), Ceftid (Cefixime Trihydrate)

Accreditations: OPL obtained ISO 9001 certification in 2000, reflecting its commitment to quality management systems.

7. Eskayef Pharmaceuticals Ltd.

One of Bangladesh’s most prominent pharmaceutical companies, Eskayef Pharmaceuticals Limited, started its glorious past in 1990 when the nation’s reputable commercial conglomerate, Transcom Group, purchased the Bangladesh branch of SK&F, USA. Through the provision of top-notch medications for Bangladesh and the rest of the world, Eskayef has built a reputation for being the pinnacle of premium quality over the last 31 years.

Head Office: Gulshan Tower, Plot No. 31, Road No. 53, Gulshan North C/A, Dhaka-1212, Bangladesh.

Factory:

Plant-1: 400, Squib Road, Industrial Area, Tongi, Gazipur, Bangladesh.

Plant-2: 2/C, North East Darus Salam Road, Mirpur-1, Dhaka-1216, Bangladesh.

Plant-3: Murapara, Rupganj, Narayanganj 1464, Bangladesh.

Total Products: Eskayef manufactures and markets a wide range of therapeutic drugs, bulk pellets, and animal health and nutrition products. Over the years, it has emerged as one of the most trusted, quality-driven, and scientific information-based companies in the eyes of healthcare professionals and patients.

Export Facilities: Eskayef has a significant global presence, exporting its medicines to 68 countries across Asia, Africa, Europe, Australia, South America, and North America. Notably, it is the first Bangladeshi pharmaceutical company to export injectable products to the USA.

Total Revenue: Approximately BDT 1,394 Crore

Growth Rate: +20.17% Year Over Year

Market Share: 3.80% in the Bangladeshi pharmaceutical market

Flagship Products: Eskayef has been at the forefront during the COVID-19 pandemic, launching three consecutive first-time generic anti-COVID medicines: Remdesivir (Remivir), Molnupiravir (Monuvir)

Nirmatrelvir co-packaged with Ritonavir (Paxovir). These medicines were exported to 49 countries worldwide.

Accreditations: Eskayef holds several prestigious global accreditations, including:

US FDA: For its oral solid and injectable manufacturing facilities.

UK MHRA: Accreditation for tablet, capsule, and sachet production lines.

EU GMP: Certification for adhering to European Union Good Manufacturing Practices.

TGA Australia: Approval for tablet, capsule, and sachet production lines.

ANVISA Brazil: Approval for both general and oncology injectable manufacturing lines.

8. Aristopharma Ltd.

Aristopharma Ltd. is a leading pharmaceutical company in Bangladesh, established in 1986 with a commitment to providing quality medicines at affordable prices.

Head Office:  7 Purana Paltan Line, Dhaka-1000, Bangladesh. Phone: +88-02-9351691-3, E-mail: info@aristopharma.com

Factory: Aristopharma operates two state-of-the-art manufacturing plants:

Shampur Plant: Situated in Shampur-Kadamtali Industrial Area.

Gachha Plant: Gachha, Gazipur.

Total Products: Around 275 brands. Including: Antiulcerants, Antibiotics, Nonsteroidal anti-inflammatory drugs (NSAIDs), Antipyretics, Vitamins and minerals, Laxatives, Cardiovascular medications, Antidiabetics, Steroids, Antispasmodics, Antihistamines, Antipsychotics, Antiemetics, Antiseptics

Export Facilities: Exports to 31 countries across 5 continents.

Total Revenue: Approximately BDT 1,288 Crore

Growth Rate: +5.23% Year Over Year

Market Share: 3.50% in the Bangladeshi pharmaceutical market

Flagship Products: Rabe (Rabeprazole Sodium), Neobion (Vitamin B1, B6 & B12), Metacard MR (Trimetazidine Dihydrochloride), Avolac (Lactulose), Rupa (Rupatadine Fumarate).

Accreditations: Aristopharma achieved the ISO 9001:2000 certification in 2005, which was later upgraded to ISO 9001:2008.

9. ACME Laboratories Ltd.

The ACME Laboratories Ltd., established in 1954, is a leading pharmaceutical company in Bangladesh, renowned for manufacturing high-quality pharmaceutical products.

Head office: 1/4, Kallayanpur, Court de la ACME, Mirpur Road, Dhaka 1207, Bangladesh.

Factory:  Dhulivita, Dhamrai, Dhaka.

Total Products: ACME produces Over 800 different types of products with 400 generics across various dosage forms, encompassing a broad range of therapeutic categories such as anti-infective, cardiovascular, antidiabetics, gastrointestinal, CNS, respiratory diseases, hormones, and steroids.

Export Facilities: The company has a significant international presence, exporting its products to regions including Southeast Asia, Africa, Central America, Europe, North America, and the CIS countries

Total Revenue: Approximately BDT 1,174 Crore

Growth Rate: +5.50% Year Over Year

Market Share: 3.20% in the Bangladeshi pharmaceutical market

Flagship Products: Monas (Montelukast Sodium), Maxima (Esomeprazole), Don-A (Domperidone Maleate), and PPI (Omeprazole).

Accreditations: WHO Prequalification GMP Certificate, UK MHRA GMP Certificate, TGA Australia GMP Certificate, ISO 9001:2015 Certification.

10. ACI Limited

Advanced Chemical Industries (ACI) Limited is one of the largest conglomerates in Bangladesh, operating across various sectors including pharmaceuticals, consumer goods, agribusiness, and retail.

One of the leading pharmaceutical companies in Bangladesh, ACI has been fostering hope and partnership for almost thirty years. The company employs over 5,000 individuals nationwide. The goal of ACI Pharma, a forward-thinking and progressive organization, is to enhance the health of Bangladeshis by introducing dependable and inventive pharmaceutical goods. Being the first business in Bangladesh to get ISO 9001 certification in 1995, ACI popularized the idea of a quality management system and continues to enhance all aspects of its business operations.

Head Office: Simpletree Anarkali (Level- 11,12,13), 89 Gulshan Avenue, Dhaka-1212, Bangladesh. (+88-02) 55068511-14

Factory: 7, Haziganj Road, Godnail, Narayangonj.

Total Products: ACI offers a comprehensive range of products across its various divisions. In the pharmaceuticals sector alone, ACI formulates and markets more than 600 Stock Keeping Units (SKUs) covering over 250 molecules in almost 100 therapeutic classes.

Export Facilities: ACI’s pharmaceuticals are exported to 33 countries across four continents. The company holds Good Manufacturing Practice (GMP) certifications from countries such as Kenya, Ivory Coast, and the Philippines, underscoring its commitment to international quality standards.

Total Revenue: Approximately BDT 1,169 Crore

Growth Rate: +8.13% Year Over Year

Market Share: 3.18% in the Bangladeshi pharmaceutical market

Flagship Products: Xeldrin (Omeprazole), Paricel (Rabeprazole Sodium), Abecab (Amlodipine Besilate + Olmesartan Medoxomil)

Accreditations: First company in Bangladesh to introduce ISO 9001-certified for quality management system (QMS) in 1995 and ISO-14001 certified for environmental management system (EMS) in 2000.

11. Radiant Pharmaceuticals Ltd.

Radiant Pharmaceuticals Limited, established in 2005, has become a prominent healthcare solution provider in Bangladesh. The company began manufacturing medicines in 2008, aiming to contribute significantly to the nation’s pharmaceutical sector.

Head Office: SKS Tower, Level 8, 7 VIP Road, Mohakhali, Dhaka 1206, Bangladesh. Office Phone Number: +880-2-9835717. Email: info@radiant.com.bd

Factory: B-46, BSCIC Industrial Estate, Tongi, Gazipur-1710, Bangladesh.

Total Products: Radiant offers over 100 registered pharmaceutical brands across various therapeutic categories.

Export Facilities: Since initiating international business operations in 2011, Radiant has expanded its reach to over 25 countries, including Canada, Kenya, Nigeria, and the Philippines.

Total Revenue: Approximately BDT 1,138 Crore

Growth Rate: +0.85% Year Over Year

Market Share: 3.09% in the Bangladeshi pharmaceutical market

Flagship Products: Some of Radiant’s leading brands include Exium (Esomeprazole), CoralCal-D (Coral Calcium + Vitamin D3), and Neucos-B (Vitamin B1, B6 & B12).

Accreditations: Radiant’s manufacturing facilities comply with Good Manufacturing Practice (GMP) guidelines set by the World Health Organization (WHO) and local regulatory requirements.

12. Popular Pharmaceuticals PLC

Popular Pharmaceuticals PLC (PPPLC), established on December 8, 2002, is a prominent pharmaceutical company in Bangladesh. The company specializes in manufacturing, marketing, promoting, and distributing a diverse range of high-quality generic pharmaceutical products.

Head Office: 17 Shukrabad, West Panthapath, Dhaka – 1207, Bangladesh. Hotline: +880-2-9101730-2,

+880-2-9102850-3.  Email: info@popular.com.bd

Factory: 164, Tongi Industrial Area, Monnunagar PS, Gazipur-1710, Bangladesh.

Total Products: The company offers 362 brands encompassing 600 dosage forms, covering a wide array of therapeutic categories.

Export Facilities: PPPLC has a strong international presence, exporting products to 32 countries across Asia, Africa, Latin America, and Europe. More than 100 products have been registered in various countries, reflecting the company’s commitment to global healthcare.

Total Revenue: Approximately BDT 1,059 Crore

Growth Rate: +19.58% Year Over Year

Market Share: 2.88% in the Bangladeshi pharmaceutical market

Flagship Products: PPPLC’s flagship products include Progut (Esomeprazole), Naspro Plus (Naproxen Sodium + Esomeprazole Magnesium), Cartibon (Glucosamine Sulfate + Diacerein), Kalcoral-D (Coral Calcium + Vitamin D3), and Hypophos (Calcium Acetate).

Accreditations: The company is ISO 9001:2015 certified for its quality management system and complies with WHO cGMP standards. PPPLC has also received GMP accreditations from various national and international regulatory bodies, including:

National Agency for the Food and Drug Administration and Control (NAFDAC), Nigeria

Philippines Food & Drug Administration

Pharmacy & Poisons Board (P&PB), Ministry of Health, Kenya

Food and Drugs Administration, Ministry of Health, Nepal

The Supreme Board of Drugs and Medical Appliances (SBDMA), Department of Health, Republic of Yemen

13. Drug International Ltd.

Drug International Limited, established in 1974, is a prominent pharmaceutical company in Bangladesh. As a pioneer in the Bangladeshi pharmaceutical industry, Drug International Limited was the first to introduce soft gelatin capsule formulations in the country, enhancing the absorption and efficacy of certain medications, such as vitamins. They also led the market by producing GYNOMIX, a soft gelatin capsule vaginal suppository with antibacterial and antifungal properties.

Head Office: 17 Bir Uttam K.M. Shafiullah Road (Green Road), Khwaja Enayetpuri (R) Tower, Dhaka-1205, Bangladesh.  Contact No.:(+880) 2 223362613-4, (+880) 2 223362621, or (+880) 2 223370257,

Factory: Tongi Industrial Area, Gazipur, Bangladesh.

Total Products: The company produces over 469 generic products, covering various therapeutic categories and dosage forms, including capsules, tablets, syrups, suspensions, injectables, suppositories, creams, and ointments.

Export Facilities: Drug International Limited exports a wide range of pharmaceutical products to 33 countries across various regions, including: USA, United Kingdom, Thailand, Myanmar, Vietnam, Somalia, Philippines, Venezuela, Togo, Nepal, Sri Lanka, Bhutan, Belarus, Bahamas, Colombia, Georgia, Ghana, Somaliland, South Africa, El Salvador, Afghanistan, Cambodia, Botswana, Nigeria, Kenya, Uganda, Honduras, Hungary, Nicaragua, Malawi, Dominican Republic, Moldova and Oman.

Total Revenue: Approximately BDT 1,023 Crore

Growth Rate: +9.06% Year Over Year

Market Share: 2.78% in the Bangladeshi pharmaceutical market

Flagship Products: Drug International Limited’s flagship products include M-Kast (Montelukast Sodium), Clopid (Clopidogrel Bisulphate), E-Cap (Vitamin E), and Dimerol (Gliclazide).

Accreditations: Drug International Limited achieved accreditations from various national and international regulatory bodies, including:

Certificate from Ministry of Public Health of Afghanistan

Certificate from Pharmacy Board of Sierra Leone

Certificate from Food and Drugs Authority Ghana

Certificate from Bangladesh Accreditaion Board

Certificate from Dept. of Drug Administration of Nepal

Certificate of Good Manufacturing from NAFDAC

Certificate from RIR Private Limited (Herbal Division)

Certificate of Registration from Registrar Corp USA (Herbal Division)

14. UniMed UniHealth Pharmaceuticals Ltd.

UniMed UniHealth Pharmaceuticals Ltd., established in 1997, is a prominent pharmaceutical company in Bangladesh. The site spans 5.22 acres and includes 17,500 square feet dedicated to production, 6,000 square feet for quality control and development laboratories, and 8,000 square feet for warehousing. The plant is equipped with modern machinery and adheres to WHO guidelines and Bangladesh’s regulatory requirements, ensuring compliance with cGMP, GLP, and ISO standards.

Head Office:  House# 660, Washpur, Post Office# Shyamlapur, Keraniganj, Dhaka 1310, Bangladesh. Contact No: +8801929993999. IP Phone: 09666-226677. E-mail: info@unigroup-bd.com

Factory: BK Bari, Mirzapur, Gazipur Sadar, Gazipur, Bangladesh. Contact No.: +8801929993291

Total Products: UniMed UniHealth offers a diverse portfolio of 333 generic products across various therapeutic categories.

Export Facilities: Exports to various countries worldwide. In July 2023, UniMed UniHealth signed a memorandum of understanding with Japan’s YAP Inc and JEC Inc to explore potential business cooperation in the pharmaceutical industry between Japan and Bangladesh, aiming to enhance pharmaceutical imports and exports between the two countries.

Total Revenue: Approximately BDT 815 Crore

Growth Rate: +15.44% Year Over Year

Market Share: 2.21% in the Bangladeshi pharmaceutical market

Flagship Products: Some of the company’s top brands include: Uromax (Tamsulosin Hydrochloride), Provair (Montelukast Sodium), Uromax-D (Tamsulosin Hydrochloride + Dutasteride), Pladex (Clopidogrel Bisulphate), Telfin (Terbinafine Hydrochloride)

Accreditations: UniMed UniHealth ensures the highest quality products by sourcing active ingredients and excipients from reputable international sources. The company’s manufacturing operations comply with cGMP, GLP, and ISO standards, with ISO certification obtained in 2012.

15. Novo Nordisk Pharma Ltd.

Novo Nordisk Pharma Pvt. Ltd. is a subsidiary of Novo Nordisk, a global healthcare company with over 90 years of innovation and leadership in diabetes care. In Bangladesh, the company has established a significant presence to address the growing challenges of diabetes in the country.

Head Office: Nina Kabbo, Level-9, 227/A, Gulshan Tejgaon Link Road, Tejgaon, Dhaka 1208, Bangladesh. Phone: +880 2 989 3701.

Factory: In partnership with Eskayef Pharmaceuticals Ltd., Novo Nordisk set up a high-tech insulin manufacturing plant in Tongi, Gazipur. This facility, inaugurated in 2012, was the company’s third in Asia after China and India. The plant produces over 5 million vials annually, adhering to Novo Nordisk’s global quality standards.

Total Products: Novo Nordisk offers a range of insulin products in Bangladesh, including Mixtard 30, Insulatard, Actrapid, NovoMix 30, NovoRapid, and Tresiba. These products cater to various needs of diabetic patients in the country.

Export Facilities: While the primary focus of the Tongi plant is to meet local demand, the establishment of such a high-tech facility underscores Bangladesh’s potential in pharmaceutical manufacturing. However, specific details about export activities from this facility are not provided.

Total Revenue: Approximately BDT 485 Crore in Bangladesh.

Growth Rate: +0.64% Year Over Year

Market Share: Leading position in the global insulin market and 1.32% in the Bangladeshi pharmaceutical market

Flagship Products: The company’s flagship insulin products in Bangladesh include:

Mixtard 30: A pre-mixed insulin formulation.

Insulatard: An intermediate-acting insulin.

Actrapid: A short-acting insulin.

NovoMix 30: A biphasic insulin aspart.

NovoRapid: A rapid-acting insulin aspart.

Tresiba: A long-acting insulin degludec.

Accreditations: The manufacturing facility in Tongi, operated in collaboration with Eskayef Pharmaceuticals Ltd., adheres to stringent quality norms practiced globally by Novo Nordisk. Eskayef has received accreditations from various international regulatory bodies, including the UK MHRA and the European Medicines Agency, ensuring that the insulin produced meets world-class standards.

16. General Pharmaceuticals Ltd.

General Pharmaceuticals Ltd. (GPL), established in 1984 and commencing operations in 1987, is a prominent pharmaceutical company in Bangladesh. GPL’s manufacturing facilities are situated in Kaliakair, Gazipur, approximately 50 kilometers north of Dhaka. The state-of-the-art factory, operational since 2011, is built in compliance with current Good Manufacturing Practices (cGMP) standards and includes modern ophthalmic and parenteral production facilities, dedicated steroidal and non-steroidal facilities, and advanced HVAC systems. The total site area is 29,792 square meters, with a building footprint of 14,444 square meters.

Head Office:  Sara Aftab Tower, 29 Ring Road, Holdings no. 6/1/A (5th Floor), Shyamoli, Adabor, Dhaka-1207. Phone: +8809639-667788, +880-2-222246297, +8809666-721212, Fax: +880-2-9120657

Factory: Unit-1: Kaliakair, Gazipur. Unit-2: Karolsurichala, Mouchak, Kaliakoir, Gazipur.

Total Products: GPL offers an extensive range of pharmaceutical products across various therapeutic classes. As of 2021, the company has developed approximately 248 dosage forms for the Bangladeshi market. Their product line includes tablets, capsules, oral liquids, injectables, ophthalmic solutions, creams, and ointments. Notable brands include Bost (Vitamin B1, B6 & B12), Multi Seas (Multivitamin & Cod Liver Oil), Oceancal-D (Coral Calcium + Vitamin D3), and Cadmin Plus (Calcium + Vitamin D3 + Multimineral).

Export Facilities: GPL has expanded its global footprint by exporting products to 24 countries in Asia, Africa, Central and South America. Including: Afghanistan, Bhutan, Cambodia, Sri Lanka, Myanmar, Hong Kong, Macau, Vietnam, Maldives, Philippines, Yemen. Tchad, Kenya, Somalia, Burkina Faso, Namibia, Botswana, Zimbabwe, Tanzania, Ethiopia, Cameroon, Jamaica, Belize, Dominican Republic

Total Revenue: Approximately BDT 429 Crore

Growth Rate: +3.80% Year Over Year

Market Share: 1.17% in the Bangladeshi pharmaceutical market

Flagship Products: Some of GPL’s flagship products include Bost (Vitamin B1, B6 & B12), Multi Seas (Multivitamin & Cod Liver Oil), Oceancal-D (Coral Calcium + Vitamin D3), and Secoclav (Cefuroxime Axetil + Clavulanic Acid).

Accreditations: The company’s manufacturing facilities comply with international standards, including certifications from UK MHRA, EU-GMP, TGA, ICH, and PIC/S, enabling GPL to meet both local and international demands.

17. Beacon Pharmaceuticals PLC

Beacon Pharmaceuticals PLC, established in 2006, is a prominent pharmaceutical company in Bangladesh, renowned for its innovative approaches to healthcare. The company transitioned to a public limited entity in 2010. Through continuous research and development, Beacon Pharmaceuticals PLC remains committed to improving the quality of human life by providing innovative pharmaceutical products, ensuring stakeholder satisfaction, and expanding its global footprint.

Head Office: 9/B, Beacon Business Centre, 2 Toyenbee Circular Road, Dhaka 1223, Bangladesh. Phone: +880-2-41054005/10. E-mail: info@beaconpharma.com.bd

Factory: The state-of-the-art manufacturing plant is situated in Bhaluka, Mymensingh.

Total Products: Beacon manufactures over 200 generic drugs and 65 oncology products. Each year, the company introduces more than 15-20 high-tech new products.

Export Facilities: After fulfilling local demand, Beacon exports its medicines to numerous countries across Asia, Africa, Europe, and Latin America.

Total Revenue: Approximately BDT 427 Crore

Growth Rate: +6.46% Year Over Year

Market Share: 1.16% in the Bangladeshi pharmaceutical market

Flagship Products: Beacon has introduced several global first generics, including: Sofosvel (Velpatasvir/Sofosbuvir), Darvoni (Sofosbuvir/Daclatasvir), Tagrix (Osimertinib), Crizonix (Crizotinib) Daclavir (Daclatasvir), Soforal (Sofosbuvir), Afanix (Afatinib), Axinix (Axitinib), Brigaix (Brigatinib), Baricinix (Baricitinib), Cabozanix (Cabozantinib), Dasanix (Dasatinib), Hernix (Neratinib), Elbonix (Eltrombopag), Ibrutix (Ibrutinib), Lenvanix (Lenvatinib), Palbonix (Palbociclib), Regonix (Regorafenib), Tofacinix (Tofacitinib), Wedica (Trelagliptin).

Accreditations: The company’s specialized cephalosporin plant has earned it the prestigious EU GMP accreditation.

18. NIPRO JMI Pharma Ltd.

NIPRO JMI Pharma Ltd. (NJPL) is a prominent pharmaceutical company in Bangladesh, established in 2012 through a collaboration with NIPRO Corporation, a multinational company based in Japan. The company is dedicated to manufacturing and marketing pharmaceutical products in compliance with current Good Manufacturing Practice (cGMP) guidelines recommended by the World Health Organization (WHO).

Head Office: Unique Heights (Level-6), 117, Kazi Nazrul Islam Avenue, Ramna, Dhaka-1217. (+88)-0255138726-8,  info@niprojmipharma.com

Factory: Rajendrapur, Chauddagram, Cumilla, Bangladesh.

Total Products: NJPL has developed 116 generic products.

Export Facilities: Exports to various 13 countries worldwide.

Total Revenue: Approximately BDT 366 Crore

Growth Rate: +11.19% Year Over Year

Market Share: 0.99% in the Bangladeshi pharmaceutical market

Flagship Products: Lijenta (Linagliptin), Empa (Empagliflozin), Doxiva (Doxophylline), Rablet (Rabeprazole Sodium),  Xinarox CV (Cefuroxime Axetil + Clavulanic Acid).

Accreditations: NJPL is committed to maintaining high-quality standards and complies with cGMP guidelines recommended by the WHO. The company has dedicated manufacturing facilities for penicillin, cephalosporin, and general formulations, along with a world-class quality control lab and modern R&D department.

19. The IBN Sina Pharmaceutical Industry Ltd.

The IBN SINA Pharmaceutical Industry PLC (IPI) is a prominent pharmaceutical company in Bangladesh, established in 1983. Named after the renowned Persian polymath Ibn Sina, the company embodies his philosophy of serving humanity through healthcare. IPI’s manufacturing facilities are situated on a 15-acre campus in Kaliakoir, Gazipur district, approximately 56 kilometers from Dhaka. Commercial production commenced in May 1986.

Initially founded as a private limited company, IPI transitioned to a public limited company in 1989 and was subsequently listed on the Dhaka Stock Exchange in 1990 and the Chittagong Stock Exchange in 1996.

Established: 1983

Head Office: The IBN SINA Pharmaceutical Industry PLC, Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur, Dhaka – 1207, Bangladesh. Phone: (+8802)41022150-58, 41022174. Fax: (+8802)41022140. Email: info@ibnsinapharma.com

Factory: Shafipur, Kaliakoir, Gazipur, Bangladesh

Total Products: Manufactures a 550+ of pharmaceutical products. Tablets, Capsules, Dry Powder for Oral Suspension/ Sachets, Syrup/ Suspension/ Solution/ Pediatric Drops, Injectables, Ophthalmic Products, Ear/ Otic Drops, Nasal Drops, Dermatological Cream/ Ointment/ Gel etc.

Export Facilities: Exports more than 100 of products to 20+ countries in Asia, Africa, USA, Central America and South America.

Total Revenue: Approximately BDT 326 Crore

Growth Rate: +4.59% Year Over Year

Market Share: 0.86% in the Bangladeshi pharmaceutical market

Flagship Products: Gavisol, Vitalgin, Sina Gold, Sina Silver, Linax E, Sinatide Cozycap, Votab, and Glipatab-M.

Accreditations: WHO cGMP compliant and ISO 9001:2015 & ISO 22000:2018 certified

20. Ziska Pharmaceuticals Ltd.

For more than 40 years, ZISKA Pharmaceuticals Ltd. has been one of Bangladesh’s top pharmaceutical enterprises. With the support, zeal, and energy of all its members, ZISKA has made steady development. Through unrelenting research and development efforts, ZISKA pledges to assist every patient by consistently introducing novel and very powerful medications. From this aim, “A Step Into Innovation,” our communication motto, was born.

Established: 1984

Corporate Address: Green City Edge, 3rd floor, 89 Kakrail C/A, Dhaka 1000, Bangladesh

Factory Address: Karol Surichala, Kaliakair. Gazipur-1751, Bangladesh

Total Products: Produces 200+ of pharmaceutical products.

Export Facilities: Exports 25+ countries worldwide.

Total Revenue: Approximately BDT 317 Crore

Growth Rate: -4.13% Year Over Year

Market Share: 0.86% in the Bangladeshi pharmaceutical market

Flagship Products: Popular brands include Dexilend (Dexlensoprazole), MM Kit (Mifepristone + Misoprostol), Misotol (Misoprostol), Xiclav (cefuroxime + Clavulanic acid), and Xitil (cefuroxime).

Accreditations: Complies with WHO cGMP compliant and ISO 9001:2015 certificates.